Chemohypersensitivity and autonomic modulation of venous capacitance in the pathophysiology of acute decompensated heart failure

Current Heart Failure Reports

Volumn 10, Issue 2, 2013, Pages 139-146

  Burchell, Amy E ^a,d   Sobotka, Paul A ^b   Hart, Emma C ^a,d   Nightingale, Angus K ^a,e   Dunlap, Mark E ^c  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b OHIO STATE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Baroreflex; Chemoreceptor; Chemosensitivity; Heart failure; Sleep disordered breathing; Splanchnic; Sympathetic; Venous capacitance

Indexed keywords

SODIUM CHLORIDE;

ACUTE HEART FAILURE; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; BODY WATER; CARDIAC PATIENT; CHEMORECEPTOR; CHEMORECEPTOR REFLEX; CHEMOSENSITIVITY; FLUID SHIFT; INTERMITTENT HYPOXIA; MORTALITY; PATHOPHYSIOLOGY; SLEEP DISORDERED BREATHING; SODIUM RETENTION; SYSTOLIC HEART FAILURE;

ACUTE DISEASE; AUTONOMIC NERVOUS SYSTEM; CHEMORECEPTOR CELLS; FLUID SHIFTS; HEART FAILURE; HUMANS; SLEEP APNEA SYNDROMES; SPLANCHNIC CIRCULATION; VASCULAR CAPACITANCE;

EID: 84883051020     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0135-y     Document Type: Article

References (62)

1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39(1):60-9.
2. NICE. CG108 Chronic heart failure: NICE guideline [Internet]. NICE. [cited 2013 Jan 14]. Available from: http://www.nice.org.uk/
3. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220.
4. Greenberg B. Acute decompensated heart failure - treatments and challenges. Circ J. 2012;76(3):532-43.
5. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442-63.
6. •• Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296-304. The CARRESS-HF trial randomised patients with ADHF and cardiorenal syndrome to treatment with stepped pharmacological (diuretic) therapy or ultrafiltration. The patients who received ultrafiltration had a similar weight loss to those treated with diuretics, but a significantly greater deterioration in renal function and rate of adverse events.
7. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007;116(14):1549-54.
8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391-479.
9. •• Lyngå P, Persson H, Hägg-Martinell A, Hägglund E, Hagerman I, Langius-Eklöf A, et al. Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial. Eur J Heart Fail. 2012;14(4):438-44. Patients with severe heart failure were randomised to either self-directed weight monitoring or intensive weight measurement using an electronic scale with the results transmitted to a heart failure centre. Intensive weight monitoring did not reduce hospitalisations or death in these patients.
10. • Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011;4(5):669-75. This review article puts forward the hypothesis that the congestion seen in ADHF is predominantly due to a rapid shift in fluid from splanchnic venous capacitance beds, and that this mechanism is driven by sympathetic over-activity.
11. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail. 2008;10(2):165-9.
12. Ponikowski P, Chua TP, Anker SD, Francis DP, Doehner W, Banasiak W, et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001;104(5):544-9.
13. Giannoni A, Emdin M, Bramanti F, Iudice G, Francis DP, Barsotti A, et al. Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure. J Am Coll Cardiol. 2009;53(21):1975-80.
14. Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology. 2008;108(4):735-48.
15. Fink GD, Arthur C. Corcoran Memorial Lecture. Sympathetic activity, vascular capacitance, and long-term regulation of arterial pressure. Hypertension. 2009;53(2):307-12.
16. Nightingale AK, Blackman DJ, Ellis GR, Schmitt M, Morris-Thurgood JA, Jones EA, et al. Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol. 2001;37(4):1062-8.
17. Schmitt M, Broadley AJM, Nightingale AK, Payne N, Gunaruwan P, Taylor J, et al. Atrial natriuretic peptide regulates regional vascular volume and venous tone in humans. Arterioscler Thromb Vasc Biol. 2003;23(10):1833-8.
18. Brunner MJ, Shoukas AA, MacAnespie CL. The effect of the carotid sinus baroreceptor reflex on blood flow and volume redistribution in the total systemic vascular bed of the dog. Circ Res. 1981;48(2):274-85.
19. Gelman S, Mushlin PS. Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology. 2004;100(2):434-9.
20. Atherton JJ, Thomson HL, Moore TD, Wright KN, Muehle GW, Fitzpatrick LE, et al. Diastolic ventricular interaction: a possible mechanism for abnormal vascular responses during volume unloading in heart failure. Circulation. 1997;96(12):4273-9.
21. Kishi T. Heart failure as an autonomic nervous system dysfunction. J Cardiol. 2012;59(2):117-22.
22. Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058-66.
23. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension. 1983;5(1):86-99.
24. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846-51.
25. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106(15):1974-9.
26. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22(2):208-15.
27. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311(13):819-23.
28. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615-21.
29. Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E, et al. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol. 2012;3:10.
30. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100(12):1049-57.
31. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60(19):1956-65.
32. Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011;58(5):839-46.
33. • Paton JFR, Sobotka PA, Fudim M, Engleman ZJ, Hart ECJ, McBryde FD, et al. The Carotid Body as a Therapeutic Target for the Treatment of Sympathetically Mediated Diseases. Hypertension. 2013;61(1):5-13. This review article focuses on the pathological effects of chemo-hypersensitivity in sympathetically mediated diseases, and considers the potential clinical therapeutic role of carotid body removal.
34. Narkiewicz K, Pesek CA, Van de Borne PJ, Kato M, Somers VK. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation. 1999;100(3):262-7.
35. Chua TP, Ponikowski P, Webb-Peploe K, Harrington D, Anker SD, Piepoli M, et al. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur Heart J. 1997;18(3):480-6.
36. Cutler MJ, Swift NM, Keller DM, Wasmund WL, Burk JR, Smith ML. Periods of intermittent hypoxic apnea can alter chemoreflex control of sympathetic nerve activity in humans. Am J Physiol Heart Circ Physiol. 2004;287(5):H2054-60.
37. Leuenberger UA, Brubaker D, Quraishi S, Hogeman CS, Imadojemu VA, Gray KS. Effects of intermittent hypoxia on sympathetic activity and blood pressure in humans. Auton Neurosci. 2005;121(1-2):87-93.
38. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension. 1988;11(6 Pt 2):608-12.
39. • Ding Y, Li Y-L, Schultz HD. Role of blood flow in carotid body chemoreflex function in heart failure. J Physiol (Lond). 2011;589(Pt 1):245-58. In this study rabbits with pacing-induced heart failure were seen to have a reduction in carotid body blood flow. When carotid body blood was reduced to a similar degree in non-paced rabbits by carotid artery occlusion, a similar increase in peripheral chemoreflex sensitivity was seen; the chemo-hypersensitivity seen in chronic heart failure is therefore likely due to poor carotid body perfusion.
40. •• Abdala AP, McBryde FD, Marina N, Hendy EB, Engelman ZJ, Fudim M, et al. Hypertension is critically dependent on the carotid body input in the spontaneously hypertensive rat. J Physiol (Lond). 2012;590(Pt 17):4269-77. Carotid body denervation in spontaneously hypertensive rats resulted in a reduction in the development and maintenance of hypertension, with an associated reduction in sympathetic vasomotor tone and an improvement in baroreflex sensitivity. These findings are consistent with the knowledge that chemoreceptor activation causes a reflex increase in sympathetic tone and, importantly, demonstrate that abolition of this sensory input can reverse autonomic pathology such as hypertension.
41. Siński M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A, et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35(5):487-91.
42. Ponikowski P, Chua TP, Piepoli M, Ondusova D, Webb-Peploe K, Harrington D, et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation. 1997;96(8):2586-94.
43. Alves MJ, dos Santos MR, Nobre TS, Martinez DG, Pereira Barretto AC, Brum PC, et al. Mechanisms of blunted muscle vasodilation during peripheral chemoreceptor stimulation in heart failure patients. Hypertension. 2012;60(3):669-76.
44. •• Despas F, Lambert E, Vaccaro A, Labrunee M, Franchitto N, Lebrin M, et al. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Hypertens. 2012;30(4):753-60. This trial looked at muscle sympathetic nerve activity (MSNA) and baroreflex sensitivity in patients with chronic heart failure. Only in those patients with chemohypersensitivity did offloading of the chemoreceptors with 100 % oxygen result in a significant decrease in MSNA and an increase in sympathetic baroreflex gain. The blunted baroreflex and raised sympathetic tone may explain the worse prognosis seen in heart failure patients with peripheral chemoreflex hypersensitivity.
45. Narkiewicz K, Van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation. 1998;97(10):943-5.
46. Vazir A, Hastings PC, Dayer M, McIntyre HF, Henein MY, Poole-Wilson PA, et al. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail. 2007;9(3):243-50.
47. Lanfranchi PA, Somers VK. Sleep-disordered breathing in heart failure: characteristics and implications. Respir Physiol Neurobiol. 2003;136(2-3):153- 65.
48. Jelic S, Le Jemtel TH. Sleep-disordered breathing in acute decompensated heart failure. Curr Heart Fail Rep. 2009;6(3):169-75.
49. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118(10):1080-111.
50. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto FJ, et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med. 2001;163(1):19-25.
51. Wang H, Parker JD, Newton GE, Floras JS, Mak S, Chiu K-L, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol. 2007;49(15):1625-31.
52. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348(13):1233-41.
53. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med. 2004;169(3):361-6.
54. Kasai T. Sleep apnea and heart failure. J Cardiol. 2012;60(2):78-85.
55. Van de Borne P, Oren R, Abouassaly C, Anderson E, Somers VK. Effect of Cheyne-Stokes respiration on muscle sympathetic nerve activity in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;81(4):432-6.
56. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92(11):3206-11.
57. Al-Hesayen A, Parker JD. Impaired baroreceptor control of renal sympathetic activity in human chronic heart failure. Circulation. 2004;109(23):2862-5.
58. Ritzema J, Troughton R, Melton I, Crozier I, Doughty R, Krum H, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121(9):1086-95.
59. • Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66. In the CHAMPION study daily measurement of pulmonary artery pressures using an implantable device resulted in a significant reduction in heart failure-related hospitalisations.
60. • Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda Jr JM, Magalski A, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51(11):1073-9. In the COMPASS-HF study remote haemodynamic measurements (right ventricular pressure, heart rate, body temperature, patient activity and estimated pulmonary arterial diastolic pressure) using an implantable Chronicle device did not significantly reduce heart failure-related events.
61. Abraham WT, Compton S, Haas G, Foreman B, Canby RC, Fishel R, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail. 2011;17(2):51-5.
62. Dunlap ME, Sobotka PA. Efficiently doing the wrong thing. J Am Coll Cardiol. 2012;60(17):1713. author reply p. 1713-1714.